Dinutuximab

Dinutuximab

PRELIMINARY SCORE

CURATIVE

DFS

NON-CURATIVE

ADJUSTMENTS

Quality of life

Not qualified for an ESMO-MCBS credit

Serious and disabling adverse effects

Other adjustments

Dinutuximab

SCORE

CURATIVE

A

Overall Survival / Disease-Free Survival / Pathological Complete Response

NON-CURATIVE

Overall Survival

Progression-Free Survival

Non-inferiority (Improved Quality of Life or Reduced Adverse Events) / Response Rate

Overall Response Rate / Duration of Response

Overall Survival / Disease-Free Survival / Pathological Complete Response

INFORMATION

Tumour type: Brain Tumours
Therapeutic Indication: <32 years old with high-risk neuroblastoma after remission and stem cell transplatation
Experimental Arm: Dinutuximab + Cis retinoic acid+GMCSF+IL2
Control Arm: Cis retinoic acid

© 2024 | **European Society for Medical Oncology** | ESMO - MCBS 1.1 | All rights reserved worldwide.